Business Wire

Milestone Study Shows Natural Molecule, Urolithin A, Can Improve Muscle Function and Life Expectancy in Mice With Muscle Dystrophy

Share

Progression of Duchenne Muscle Dystrophy (DMD) can be delayed in mice by supplementing their diets with Urolithin A, according to new results reported today. The findings, published in Science Translational Medicine, raise hopes that new treatment options could one-day be developed for DMD, an uncurable genetic condition characterized by progressive muscle degeneration. About 1 in 3,500 boys are born with DMD, which usually develops in childhood and significantly reduces life expectancy.

The new research carried out at the laboratory of Professor Johan Auwerx, MD, PhD at the Swiss Federal Institute of Technology EPFL and the University of Lausanne in collaboration with scientists at the Swiss life science company Amazentis, highlights the important role that defective mitochondria can play in DMD. The powerhouses of cells, mitochondria produce the energy necessary for normal muscle function. But muscle cells taken from both human DMD patients and from mice bred to mimic the condition show significant defects in mitochondrial activity, the study finds. Specifically, patterns of gene expression show the development of DMD is associated with a marked decrease in mitophagy – the process cells rely on to remove and recycle defective mitochondria and maintain energy levels high.

“Duchenne Muscle Dystrophy is the most common fatal genetic disease diagnosed in childhood with still no cure available,” says Johan Auwerx, MD, PhD, lead-author and Professor at the EPFL. “Our work represents a significant breakthrough in the search for new therapeutic approaches for muscular dystrophies.”

The natural compound Urolithin A is known to activate mitophagy and improve mitochondrial health in both mice and humans. When the study scientists and lead authors, Peiling Luan and Davide D’Amico, fed the compound to DMD mice for just ten weeks, they saw mitophagy levels rise effectively restoring them to normal. This led to a significant reduction of muscle damage and improvement in muscle health and performance. The DMD mice administered Urolithin A saw grip strength increase by 31% and running performance increase by 45% compared with control untreated animals. And they lived longer – survival increased by 40%.

Importantly for the human disease, Urolithin A reduced a damaging condition called fibrosis in muscles of the DMD mouse heart and diaphragm by 36% and 39%, respectively. Similar damage seen in DMD patients typically leads to fatal cardiac or respiratory failure. Urolithin A was also able to enhance the regeneration of mouse muscle stem cells. This is particularly relevant to the disease in humans as the onset of DMD is linked with the exhaustion of functional stem cells.

Davide D’Amico, PhD, Project Leader at Amazentis and a first author of the paper, said: “Prior to this study, it was understood that the dramatic loss of muscle function in DMD patients was associated with mitochondrial dysfunctions. Here we discovered that defective mitophagy, the removal and recycling of dysfunctional mitochondria, plays a key role in the progression of DMD.”

Chris Rinsch, PhD, Co-founder and CEO of Amazentis, said, “The rigorous science being published in Science Translational Medicine strengthens the scientific evidence of Urolithin A as a potent enhancer of muscle function. It’s exciting to see this natural metabolite can support not only healthy muscle, but also shows promise for progressive muscle diseases in pre-clinical research.”

The results are reported in the current issue of Science Translational Medicine in the article: “Urolithin A improves muscle function by rescuing mitophagy in muscular dystrophy”.

Background on Urolithin A

Amazentis’ proprietary lead product is an oral formulation of Urolithin A. Urolithin A is a microflora-derived metabolite of ellagitannins, a class of compounds found in the pomegranate and other fruits and nuts. Administration of Urolithin A leads to improved mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, stimulating growth of healthy mitochondria. Mitophagy declines in cells as we age, and the reduction in mitochondrial function in the muscles is thought to be one of the main causes of age-related muscle decline. Previously, Amazentis and the EPFL reported preclinical results in Nature Medicine in an article titled, “Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents” (doi:10.1038/nm.4132) and clinical results showing Urolithin A’s safety, bioavailability and its impact on biomarkers of mitochondrial health in Nature Metabolism in an article entitled “The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans (doi: 10.1038/s42255-019-0073-4). For more information, please visit www.mitopure.com.

About Amazentis

Amazentis is an innovative life science company that employs today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. The company has recently concluded two clinical trials evaluating the benefits of Urolithin A on skeletal muscle in healthy adults. For more information on Amazentis, please visit www.amazentis.com.

Contact information

Federico Luna
Chief Marketing Officer Amazentis
press@amazentis.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CGTN: A City on the Rebound: How Hong Kong Can Move Forward13.4.2021 19:57:00 CEST | Press release

The past two years have been tough on the world, not just due to the pandemic but also the geopolitical volatility that has roiled many countries and regions. In East Asia, the financial hub of Hong Kong has experienced its fair share of difficulties, but as life slowly returns to normal, problems that have plagued the city for decades remain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413006039/en/ (Photo: Business Wire) The city's brief history is well-documented – its humble industrialization in the 1970s coupled with the entrepreneurial spirit of its residents saw it become a bastion of wealth at a time when that part of the world was still economically stagnant. Coupled with a liberalized financial system and generous policies, the city catapulted itself toward the top, competing with mega-cities such as London and New York City. For all its glitz and glamour, Hong Kong contained contradictions that boiled over i

Tigo Intellectual Property Infringement Lawsuit against APS Continues to Grow13.4.2021 19:53:00 CEST | Press release

Tigo Energy, Inc., the solar industry worldwide leader in Flex-MLPE (Module Level Power Electronics), has filed a new lawsuit against Altenergy Power Systems (“APsystems”), in addition to its current ongoing case. The complaint includes four new patent infringement claims, as well as an additional claim from a patent asserted in the previously-filed lawsuit. The complaint was filed in the United States District Court for the Northern District of California. The total number of Patents-in-Suit in both cases now stands at six. The complaint includes all APsystems legal entities in the US as well as in China. The new complaint alleges that APsystems’ Sunspec-compliant products infringe the following U.S. patents: 8,653,689, 9,584,021, 9,966,848, 10,333,405, and 8,933,321. The complaint centers around various systems and methods used in the PV module rapid shutdown unit. Tigo’s industry leading solar equipment provides optimized, monitored and safe solar to protect this critical infrastruc

Maxon Announces Cinema 4D S2413.4.2021 18:05:00 CEST | Press release

Maxon, the developers of professional software solutions for motion designers and visual effects artists, today announced Cinema 4D Subscription Release 24 (S24). The latest subscription-only release of Maxon’s 3D application allows users to easily browse and obtain models, materials and other assets, and to intuitively place them within the scene. The release also includes key workflow enhancements and a sneak peek at continued progress on the Scene Nodes and Scene Manager interfaces to the new core. Cinema 4D S24 is immediately available for subscription customers. For perpetual license holders of Cinema 4D a release is scheduled later this year that will incorporate the features of S24, as well as future enhancements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005918/en/ Maxon Cinema 4D S24 features placement tools, a new asset browser, animation workflow enhancements, and continued development on powerful nodes

Maxon Announces Redshift for macOS Including Native Support for M1-Powered Macs13.4.2021 18:05:00 CEST | Press release

Today, Maxon announced the immediate availability of Redshift for macOS including support for M1-powered Macs as well as Apple’s Metal Graphics API. Redshift, the award-winning, production-ready renderer, offers a rich feature set including ray switches, flexible shading networks, motion blur, AOVs, deep output, layered EXR and much more. Unlike other GPU renderers, Redshift is a biased renderer that enables artists to adjust the quality of individual techniques in order to get the best performance/quality balance for production. As a Universal solution, Redshift is optimized for high-end performance across both M1- and Intel-powered Macs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005903/en/ Redshift for macOS signifies a milestone, bringing cutting-edge cinematic rendering to Mac artists. (Graphic: Business Wire) Redshift for macOS signifies a milestone, bringing cutting-edge cinematic rendering to Mac artists. A

Golden Euro-spiller tok rekordgevinst på € 3 millioner13.4.2021 17:29:00 CEST | Pressemelding

Champagnen flyter og feiringen er godt i gang hos Golden Euro Casino, etter at en heldig spiller tok jackpoten og vant en monstergevinst på € 3 746 291. Spillerens gevinst kom på Realtime Gamings enormt populære automat Aztec Millions. Det er den største gevinsten gjennom tidene på det progressive jackpotspillet, og hos Golden Euro. For å starte økten gjorde den 49 år gamle spilleren et kredittkortinnskudd på € 27, og hentet Golden Euros ettertraktede innskuddsbonus på 50 %. Dermed hadde hun € 54 til å spille med. Gevinsten kom fra en liten enkeltinnsats på € 5 plassert fra smarttelefonen hennes. Da hjulene stoppet opp og jackpoten ble utløst, ble spilleren umiddelbart mangemillionær. Adrian Berger hos Golden Euro Casino uttaler: “Vi er så glade for at en av spillerne våre har landet den største jackpotgevinsten noensinne på Realtime Gamings Aztec Millions. “Jeg snakket med spilleren kort tid etter at hun bekreftet gevinsten sin og hun var utrolig opprømt, selv om det at hun nå er en m

Agthia Embarks on Transformational Journey with its Strategy to Become an F&B Leader by 202513.4.2021 17:06:00 CEST | Press release

Agthia Group PJSC revealed its long-term strategy to become an F&B leader in the Middle East, North Africa and Pakistan (MENAP) region and beyond by 2025. The strategy is built on three strategic pillars (growth, efficiency and capability) and is designed to extend the Group’s market leadership, provide significant value for all stakeholders and continue to drive profitability growth with a consumer-centric approach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005841/en/ Khalifa Sultan Al Suwaidi - Chairman - Agthia Group (Photo: AETOSWire) The Abu Dhabi-based organisation is engaged in manufacturing, distribution and marketing of a wide range of F&B products, including popular regional brands such as Al Ain (water), Al Foah (dates), Al Faysal Bakery & Sweets (bakery) and Grand Mills (flour and bakery) among others. Khalifa Sultan Al Suwaidi, Chairman, Agthia Group, said: “The strategy will unleash the full potentia

FRISS Acquires Terrene Labs to Expand Underwriting Efficiency13.4.2021 17:03:00 CEST | Press release

FRISS, the market leader in AI-powered fraud, risk and compliance solutions for P&C insurance carriers, today announced the acquisition of Terrene Labs. Industry leaders in providing Commercial Insurance providers with comprehensive Risk Insights, Terrene will be a fundamental addition to the FRISS product family. Commercial lines underwriters now have access to thousands of actionable insights within just 5 seconds, replacing a disjointed manual and limited enrichment process that previously took up to a week and delayed policies for quality customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005837/en/ FRISS acquires Terrene Labs and welcomes them to their family. (Graphic: Business Wire) “We’re bringing commercial lines to the digital age together,” remarked FRISS CEO and Co-founder Jeroen Morrenhof. “True risk insights were always hard to access and we’re changing that. Combined with the analytics capabilitie